Key points from article :
Vowst, the first FDA-approved pill made from healthy bacteria in human waste, treats recurring C. diff infections in adults.
The new treatment from Seres Therapeutics provides a simpler, rigorously tested version of stool-based procedures.
Vowst offers a less invasive alternative to traditional stool transplants via colonoscopy or enema.
Four daily capsules taken for three days, containing healthy gut bacteria from screened donors.
While stool banks may see less demand, some (like OpenBiome) remain open for ineligible patients.
Seres Therapeutics markets Vowst with Nestle, aiming for a smooth physician and patient experience.
The FDA warns of potential infection and allergen risks, despite rigorous manufacturing processes.
Studies show 88% of Vowst recipients avoided reinfection after 8 weeks, compared to 60% with placebo
